While the strategies didn’t lower NT-proBNP after PCI in acute MI patients, they may suggest a way forward for intervening early.

The study should be the first of many helping to understand the negative CV effects of the drug in an illicit setting, say authors.

In hypothetical situations, physicians chose intensive treatment more often if BP and mobility metrics were available.

PE or PEERLESS, the choice of therapy was shifting, influenced by patient factors and institutional protocols.

Operative mortality fell over time, but there was a concerning uptick in recent years attributed to low-volume sites.

There was a consensus that more data are needed to answer this question, with discussions about what such a trial would look ...

Outcomes and expenses were similar with transplant and elective LVAD, but urgent LVAD after ECMO fared much worse.

Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

More inclusive research on bleeding could enable better care for medically managed patients, not just those who get PCI.

Daniel Burkhoff and Akshay Desai discuss the innovative technologies and late-breaking science presented at day 2 of THT.